News
Proteapex Therapeutics in the News
February 13, 2024
Dr. D’Angelo, our CSO, will pitch our osteoarthritis products at the Philly Life Science Tech Transfer Showcase, hosted by BioStrategy Partners and BioLabs Philadelphia (https://www.biostrategypartners.org/event-5552994). In addition, ProteaPex Therapeutics will present posters on our dietary supplement product development and our platform technology of the Extracellular Matrix Protection Factors and their therapeutic value in several diseases.
October 2023
ProteaPex Therapeutics presented a virtual poster of our proof-of-concept data on the efficacy of ECPF-1 injectable therapeutic in slowing the progression of osteoarthritis in a rat model for the American Society of Bone and Mineral Research Conference held in Montreal, Canada (https://www.asbmr.org/meetings/past-ASBMR-meetings).
May 11, 2023
ProteaPex Therapeutics was invited to present in the “Most Exciting BioScience Research” poster session for Delaware’s DNA Life Sciences Conference in Claymont, Delaware. Our CSO presented a poster on the development and candidate screening for our dietary supplement that targets pain and inflammation in osteoarthritis.
March 25-27, 2023
Dr. D’Angelo gave a talk highlighting our latest data on ECPF-2’s therapeutic enhancement of elastin production in diseased cells from pulmonary fibrosis patients with chronic obstructive pulmonary disease at the Anatomy Connected Conference of the American Association for Anatomy in Washington, DC (https://anatomy2023.eventscribe.net/).
April 2-5, 2022
During the Experimental Biology Conference in Philadelphia, PA, (https://www.eventscribe.net/2022/EB2022/) Proteapex Therapeutics presented our proof-of-concept data demonstrating ECPF-2’s role as a potential therapeutic in treatment of the pulmonary fibrosis in chronic obstructive pulmonary disease.
December 2-16, 2020
ProteaPex Therapeutics presented three posters at the American Society for Cell Biology, Cell-Bio Virtual conference (https://www.ascb.org/cellbiovirtual2020/) Data supporting the therapeutic efficacy of ECPF-2’s reduction of inflammation and collagen degradation in primary gingival fibroblast cultures were highlighted.
July 24, 2019
Dr. Marina D’Angelo, CSO, will pitch ECPF-2, the novel therapeutic to treat periodontal disease, to Fortune 500 companies and investors. The pitch was coordinated through the National Council of Entrepreneurial Tech Transfer (NCET2).
April 23, 2018
ProteaPex Therapeutics is presenting several posters at the 2018 Experimental Biology meeting in San Diego, CA. In addition, we are featured in a short film as part of the Thought Leadership Series.
See the film here
March 9, 2018
ProteaPex Therapeutics won First Place on March 9 in the Orthopedic Research Society's First Annual Business Plan Competition in New Orleans, Louisianna. They detailed the business plan for their lead therapeutic, Pexagen, an injectable osteoarthritis treatment for companion animals.
February 26, 2018
ProteaPex Therapeutics has been chosen as a top 5 finalist in the Orthopedic Research Society's Business Innovation Competition. CSO, Marina D'Angelo, will pitch to an expert panel of judges on March 9 in New Orleans.
February 26, 2018
ProteaPex Therapeutics will be the subject of a short documentary in the Thought Leadership Film Series produced by WebsEdge. The documentary will air on EBTV during the Experimental Biology Conference in San Diego this April 2018.
February 13, 2018
ProteaPex Therapeutics was awarded their third patent, COMPOSITIONS AND METHODS FOR INHIBITION OF MMP8:MMP8-SUBSTRATE INTERACTIONS for their novel therapeutic ECPF-2.
April 22, 2017
Two scientific posters detailing our ECPF therapeutics will be presented this week at the Experimental Biology meeting in Chicago, Illinois (April 22-26, 2017).
November 14, 2016
Our periodontal disease therapeutic, ECPF-2, is the subject of a proof-of-concept competition grant proposal to the University City Science Center. The winners will be announced early 2017.
See the video here
April 2, 2016
Three scientific posters detailing our ECPF therapeutics will be presented this week at the Experimental Biology meeting in San Diego, California (April 2-6, 2016). One of the ECPF1 presentations is a finalist for the American Association of Anatomists Undergraduate Student Poster Award.
July 24, 2019
Dr. Marina D’Angelo, CSO, will pitch ECPF-2, the novel therapeutic to treat periodontal disease, to Fortune 500 companies and investors. The pitch was coordinated through the National Council of Entrepreneurial Tech Transfer (NCET2).
October 30, 2015
ProteaPex Therapeutics has been invited to participate in this year's Life Science Futures Partnerships in Sciences Symposium to be held in Philadelphia,PA.
http://lifesciencesfuture.com/symposium-partnerships-in-science/
Marina D'Angelo, CSO, will present osteoarthritis animal model data of efficacy for ECPF-1 as a therapeutic and human tooth model data of efficacy of ECPF-2 as a therapeutic in stabilizing dental restoration bonding.
October 13, 2015
SECOND PATENT GRANTED TO PROTEAPEX THERAPEUTICS
ProteaPex Therapeutics has been granted its second patent on the"Compositions and Methods for Inhibition of MMP:MMP-Substrate Interactions" by the US Patent Office.ProteaPex Therapeutics has developed an innovative disease modifying therapeutic technology with applications in the treatment of post-traumatic osteoarthritis and durability of dental restorations. The family of peptide inhibitors, Extracellular Matrix Protection FactorsT (ECPF) represent a broad base of products for treatment of orthopedic, dental and wound healing health issues.
September 3, 2015
Marina D'Angelo, PhD, CSO and co-founder of ProteaPex Therapeutics, was the recent subject of a Faculty Spotlight.
See the video here
May 8, 2015
Our lead OA product, ECPF-1, was recently featured on public radio in a segment on pet osteoarthritis. You can listen to it here: https://www.insidehighered.com/audio/2015/05/04/canine-osteoarthritis
Listen here
March 31, 2015
ProteaPex Therapeutics participated in a platform presentation at the Experimental Biology meeting in Boston, MA entitled "Development of a Serum-free, Three Dimensional Cell Culture Model for Primary Human Articular Chondrocytes to Test Potential Therapeutics".
News from 2013
PATENT GRANTED TO PROTEAPEX THERAPEUTICS
December 16, 2013ProteaPex Therapeutics has been granted a patent on the "Compositions and Methods for Inhibition of MMP13:MMP-Substrate Interactions” by the US Patent Office.
ProteaPex Therapeutics has developed an innovative disease modifying therapeutic technology to treat post-traumatic osteoarthritis PTOA, Extracellular Matrix Protection Factor™ (ECPF-1). This is a novel, safe and effective intra-articular injection that reduces the pain and damage caused by OA by targeting individual protein pairs.
In addition, using ECPF-1, ProteaPex Therapeutics is developing a broad base of products for treatment of orthopedic, periodontal and wound healing health issues.
Jeff Boily, ProteaPex's Chairman will be part of the Selection Committee panel at the 2013 Animal Health Investment Forum. The KC Animal Health Investment Forum provides a unique opportunity for venture capital funds, investment firms and animal health companies to hear from emerging companies with the newest technology.
NEWS FROM 2012
ProteaPex Therapeutics (as ChondroPro Biosciences) won the People's Choice Award in the 2012 Wharton Business Plan Competition. More...
ProteaPex Therapeutics Presents New Designs for Fracture Non-Union Therapeutics in San Diego, CA at the American Society of Bone and Mineral Research Annual Meeting